NASDAQ: HYPRHyperfine Inc Stock
$0.74+0.01 (+1.37%)
Updated Jun 27, 2025
HYPR Price
$0.74
Fair Value Price
N/A
Market Cap
$57.76M
52 Week Low
$0.53
52 Week High
$1.90
P/E
-1.37x
P/B
1.34x
P/S
4.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.73M
Earnings
-$40.29M
Gross Margin
46.2%
Operating Margin
-343.42%
Profit Margin
-343.4%
Debt to Equity
0.24
Operating Cash Flow
-$36M
Beta
1.12
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HYPR Overview
Hyperfine, Inc., a medical device company, created Swoop, a portable MRI system that produces images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose and treat patients in various clinical settings. Swoop can be wheeled directly to the patient's bedside, plugged into a standard electrical wall outlet, and controlled by an iPad. The company was incorporated in 2014 and is based in Guilford, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HYPR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
HYPR
Ranked#105 of 106
Ranked#105 of 106
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $12.21 | A | |
| $30.22 | A | |
| $21.99 | A |
Be the first to know about important HYPR news, forecast changes, insider trades & much more!
HYPR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HYPR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HYPR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HYPR is good value based on its book value relative to its share price (1.34x), compared to the US Medical Devices industry average (4.1x)
P/B vs Industry Valuation
HYPR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HYPR due diligence checks available for Premium users.
Valuation
HYPR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.37x
Industry
36.87x
Market
32.24x
HYPR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.34x
Industry
4.1x
HYPR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HYPR's financial health
Profit margin
Revenue
$2.1M
Net Income
-$9.4M
Profit Margin
-440.7%
HYPR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HYPR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.4M
Liabilities
$10.3M
Debt to equity
0.24
HYPR's short-term assets ($48.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HYPR's short-term assets ($48.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HYPR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.2M
Investing
-$472.0k
Financing
$5.6M
HYPR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HYPR vs Medical Device Stocks
Hyperfine Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.